Compare Cytokinetics Inc (CYTK) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ServiceNow Inc — how do they compare? Cytokinetics Inc trades at $81.56 (market cap $11.12B), while ServiceNow Inc trades at $106.69 (market cap $108.13B). The key difference: ServiceNow Inc is far larger — about 9.7× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | NOW | |
|---|---|---|
Market Cap | $11.12B | $108.13B |
Sector | Technology | Technology |
52-Week High | $87.26 | $199.24 |
52-Week Low | $33.23 | $83.00 |
Enterprise Value | $11.59B | $105.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
ServiceNow (NOW) trades at $111.26, up 3.3% on the day, with a bullish technical signal and strong fundamental growth. Revenue grew to $13.28B in 2025, with net income of $1.75B, though valuation ratios like P/E of 62.41 are elevated. Recent news highlights AI-driven growth opportunities, with the stock gaining 41% in May 2026 (Fool, 2026-06-03).
The outlook remains positive with an 85.51% analyst buy rating and a $137.41 consensus price target, implying significant upside. Risks include high valuation sensitivity and competitive pressures in enterprise AI. Cash flow trends show operational strength, but 2026 projections indicate potential net outflow, warranting monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
